M. Beau-Faller

发表

A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma

Pierre Validire, Philippe Girard, Paul Hofman, 2012, Clinical Cancer Research.

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

Jean Mosser, Franck Morin, Gérard Zalcman, 2016, The Lancet.

Allelic imbalance at loci containing FGFR, FGF, c-Met and HGF candidate genes in non-small cell lung cancer sub-types, implication for progression.

M. Gaub, E. Guérin, E. Quoix, 2003, European journal of cancer.

Genetic heterogeneity in lung and colorectal carcinoma as revealed by microsatellite analysis in plasma or tumor tissue DNA

D. Jaeck, M. Gaub, E. Guérin, 2003, Cancer.

Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas†

G. Inghirami, M. Schaeffer, E. Ruffini, 2017, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Specificities of Lung Adenocarcinoma in Women Who Have Never Smoked

P. Validire, J. Mazières, P. Hofman, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

J. Mazières, J. Merlio, F. Escande, 2020, JTO clinical and research reports.

Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung.

M. Antoine, M. Wislez, M. Beau-Faller, 2014, Lung cancer.

Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer.

M. Schaeffer, E. Guérin, E. Quoix, 2016, Future oncology.

Rare epidermal growth factor receptor (EGFR) mutations in 10,117 patients with non-small cell lung cancer (NSCLC) evaluated by the French ERMETIC IFCT network: Clinical, molecular, and survival data.

J. Solassol, H. Blons, F. Escande, 2012 .

IFCT0401-bio phase II trial: Gefitinib administered as 1st-line in non-resectable adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC)—Predictive biomarkers of efficacy and survival

E. Brambilla, F. Coulet, M. Antoine, 2008 .

Prognostic Value of Exon 19 Versus 21 EGFR Mutations Varies According to Disease Stage in Surgically Resected Non-small Cell Lung Cancer Adenocarcinoma

E. Ruffini, J. Vignaud, N. Santelmo, 2018, Annals of Surgical Oncology.

Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery

M. Schaeffer, M. Beau-Faller, P. Falcoz, 2016, British Journal of Cancer.

Epidermal growth factor receptor and v-Ki-ras2 Kirsten rat sarcoma viral oncogen homologue-specific amino acid substitutions are associated with different histopathological prognostic factors in resected non-small-cell lung cancer.

M. Schaeffer, M. Chenard, N. Santelmo, 2016, Interactive cardiovascular and thoracic surgery.

Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients

E. Guérin, C. Maugard, B. Mennecier, 2014, European Respiratory Review.

Brief report : High MET overexpression does not predict the presence of MET exon 14 splice mutations in NSCLC : results from the IFCT Predict.amm study.

M. Copin, D. Moro-Sibilot, F. Barlesi, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Reply to the letter to the editor 'Prevalence of rare EGFR mutations in non-small cell lung cancer: a multicenter study on 3856 Polish Caucasian patients' by Krawczyk et al.

M. Beau-Faller, J. Cadranel, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases

D. Planchard, J. Adam, C. Caramella, 2019, Journal of Thoracic Oncology.

Use of magnetic beads for plasma cell-free DNA extraction: toward automation of plasma DNA analysis for molecular diagnostics.

M. Gaub, E. Guérin, E. Quoix, 2003, Clinical chemistry.

A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.

J. Pignon, J. Mosser, I. Bièche, 2014, The Journal of molecular diagnostics : JMD.

Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study

Franck Morin, Patrick Merle, Pascal Auquier, 2018, European Respiratory Journal.

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.

F. Cappuzzo, S. Peters, J. Mazières, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.

S. Peters, E. Felip, J. Mazières, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy

P. Laurent-Puig, E. Tartour, H. Blons, 2017, Oncoimmunology.

Association of genetic defects in primary resected lung adenocarcinoma revealed by targeted allelic imbalance analysis.

F. Alla, C. Bronner, M. Gaub, 2002, American journal of respiratory cell and molecular biology.

Genomic Aberrations in Lung Adenocarcinoma in Never Smokers

B. Job, P. Dessen, A. Bernheim, 2010, PloS one.

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort

M. Gaub, E. Guérin, E. Quoix, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.

J-L Pretet, I. Bièche, J. Solassol, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project.

H. Blons, J. Merlio, F. Escande, 2020, Lung cancer.

Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France

J. Mosser, J. Mazières, J. Sabourin, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer

J. Mazières, G. Favre, I. Rouquette, 2014, Clinical Cancer Research.

Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) bio

H. Blons, J. Merlio, F. Escande, 2019, Lung cancer.

Lung Adenocarcinoma with Pulmonary Miliary Metastases and Complex Somatic Heterozygous EGFR Mutation

E. Quoix, B. Mennecier, M. Beau-Faller, 2014, Case Reports in Oncology.

Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance

C. Mascaux, E. Guérin, L. Vallat, 2022, Cancers.

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program

J. Mosser, H. Blons, J. Merlio, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma.

M. Wislez, M. Beau-Faller, J. Cadranel, 2013, Critical reviews in oncology/hematology.

Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring

C. Mascaux, E. Guérin, L. Vallat, 2021, Cancers.

Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC/ATS/ERS classification

M. Gaub, J. Ghnassia, E. Quoix, 2015, Pathology.

MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early–stage lung cancer patients from the IFCT-0002 Phase 3 Trial

F. Galateau-Sallé, E. Brambilla, O. Molinier, 2016, Oncotarget.

An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial

P. Hainaut, B. Milleron, E. Brambilla, 2012, Clinical Cancer Research.

SNAI2 and TWIST1 in lymph node progression in early stages of NSCLC patients

E. Guérin, E. Quoix, M. Chenard, 2018, Cancer medicine.

Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases

M. Chenard, D. Guenot, N. Santelmo, 2015, British Journal of Cancer.

Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2).

J. Pignon, H. Blons, G. Zalcman, 2019, Clinical lung cancer.

EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up

M. Gaub, E. Guérin, E. Quoix, 2008, European Respiratory Journal.

Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma.

P. Validire, J. Soria, A. Bernheim, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.

J. Mosser, D. Planchard, J. Merlio, 2019, European journal of cancer.

Plasma DNA microsatellite panel as sensitive and tumor‐specific marker in lung cancer patients

M. Gaub, E. Quoix, E. Weitzenblum, 2003, International journal of cancer.

KRAS‐specific Amino Acid Substitutions are Associated With Different Responses to Chemotherapy in Advanced Non–small‐cell Lung Cancer

E. Quoix, M. Chenard, B. Mennecier, 2018, Clinical lung cancer.

Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts).

J. Mosser, F. Penault-Llorca, J. Soria, 2013 .

Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping

M. Gaub, E. Guérin, E. Quoix, 2009, British Journal of Cancer.

Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer

C. Mascaux, M. Beau-Faller, E. Pencreach, 2023, International journal of molecular sciences.

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice

J. Mosser, J. Mazières, G. Zalcman, 2017, European Respiratory Journal.

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.

J. Mosser, H. Blons, J. Merlio, 2017 .

Patient-Derived Tumoroid for the Prediction of Radiotherapy and Chemotherapy Responses in Non-Small-Cell Lung Cancer

N. Benkirane-Jessel, F. Fioretti, V. Lindner, 2023, Biomedicines.

Use of Ras effector RASSF1A promoter gene methylation and chromosome 9p loss of heterozygosity (LOH) to predict progression-free survival (PFS) in perioperative chemotherapy (CT) phase III trial IFCT-0002 in resectable non-small cell lung cancer

B. Milleron, G. Zalcman, E. Bergot, 2008 .

Inequity in access to personalized medicine in France: Evidences from analysis of geo variations in the access to molecular profiling among advanced non-small-cell lung cancer patients: Results from the IFCT Biomarkers France Study

W. Weeks, B. Ventelou, F. Barlesi, 2020, PloS one.

A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma

P. Validire, J. Soria, J. Mazières, 2012, Clinical Cancer Research.

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.

J. Mazières, R. Rosell, F. Barlesi, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Lung Cancer Harboring Her2 Mutation: Epidemiological Characteristics and Therapeutic Perspectives

J. Mazières, F. Barlesi, B. Besse, 2012 .

RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer

J. Mazières, G. Favre, I. Rouquette, 2014, Clinical Cancer Research.

Non-small cell lung cancer, early stage

L. Bubendorf, T. Yamanaka, M. Okada, 2012 .